These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 23391364)
1. Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents. Yang W; Hu Y; Yang YS; Zhang F; Zhang YB; Wang XL; Tang JF; Zhong WQ; Zhu HL Bioorg Med Chem; 2013 Mar; 21(5):1050-63. PubMed ID: 23391364 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents. Wang HH; Qiu KM; Cui HE; Yang YS; Yin-Luo ; Xing M; Qiu XY; Bai LF; Zhu HL Bioorg Med Chem; 2013 Jan; 21(2):448-55. PubMed ID: 23245802 [TBL] [Abstract][Full Text] [Related]
3. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase. Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents. Lv PC; Li HQ; Sun J; Zhou Y; Zhu HL Bioorg Med Chem; 2010 Jul; 18(13):4606-14. PubMed ID: 20627597 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors. Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957 [TBL] [Abstract][Full Text] [Related]
6. Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors. Yang B; Yang YS; Yang N; Li G; Zhu HL Sci Rep; 2016 Jun; 6():27571. PubMed ID: 27273260 [TBL] [Abstract][Full Text] [Related]
7. Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma. Yu M; Yang H; Wu K; Ji Y; Ju L; Lu X Bioorg Med Chem; 2014 Aug; 22(15):4109-18. PubMed ID: 24934992 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents. Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors. Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N'-phenylureas and thioureas as antitumor agents. Li HQ; Yan T; Yang Y; Shi L; Zhou CF; Zhu HL Bioorg Med Chem; 2010 Jan; 18(1):305-13. PubMed ID: 19914837 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity. Li HQ; Li DD; Lu X; Xu YY; Zhu HL Bioorg Med Chem; 2012 Jan; 20(1):317-23. PubMed ID: 22112541 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors. Qiu KM; Wang HH; Wang LM; Luo Y; Yang XH; Wang XM; Zhu HL Bioorg Med Chem; 2012 Mar; 20(6):2010-8. PubMed ID: 22361272 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents. Li QS; Lv XH; Zhang YB; Dong JJ; Zhou WP; Yang Y; Zhu HL Bioorg Med Chem Lett; 2012 Nov; 22(21):6596-601. PubMed ID: 23025996 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors. Zhang YB; Wang XL; Liu W; Yang YS; Tang JF; Zhu HL Bioorg Med Chem; 2012 Nov; 20(21):6356-65. PubMed ID: 23018096 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and molecular modeling of 1,3,4-thiadiazol-2-amide derivatives as novel antitubulin agents. Li YJ; Qin YJ; Makawana JA; Wang YT; Zhang YQ; Zhang YL; Yang MR; Jiang AQ; Zhu HL Bioorg Med Chem; 2014 Aug; 22(15):4312-22. PubMed ID: 24909678 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors. Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and molecular docking of α,β-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity. Xu YY; Cao Y; Ma H; Li HQ; Ao GZ Bioorg Med Chem; 2013 Jan; 21(2):388-94. PubMed ID: 23245570 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel pyrazoline-containing derivatives as potential tubulin assembling inhibitors. Qin YJ; Li YJ; Jiang AQ; Yang MR; Zhu QZ; Dong H; Zhu HL Eur J Med Chem; 2015 Apr; 94():447-57. PubMed ID: 25828827 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors. Li S; Guo C; Zhao H; Tang Y; Lan M Bioorg Med Chem; 2012 Jan; 20(2):877-85. PubMed ID: 22182581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]